Invitae Corporation (NVTA)
|Net Income (ttm)||-451.37M|
|Day's Range||2.26 - 2.73|
|52-Week Range||1.83 - 32.93|
|Price Target||6.20 (+146.0%)|
|Earnings Date||Aug 9, 2022|
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development,... [Read more...]
In 2021, Invitae's revenue was $460.45 million, an increase of 64.68% compared to the previous year's $279.60 million. Losses were -$379.01 million, -37.06% less than in 2020.Financial Statements
According to 16 analysts, the average rating for NVTA stock is "Buy." The 12-month stock price forecast is 6.2, which is an increase of 146.03% from the latest price.
SAN FRANCISCO , Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9,...
An analyst downgrades his recommendation on the stock, making a brutal cut to his price target while doing so.
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The genetic-testing company had a lot of news that investors didn't like.
Invitae (NVTA) stock is falling on Tuesday after the biotechnology company revealed plans to cut costs as part of a strategic realignment. The post Invitae (NVTA) Stock Falls 12% on Cost-Cutting Plan ap...
Invitae Corp (NYSE: NVTA) plans to focus its resources on higher-margin and higher-growth businesses, including oncology, women's health, rare disease, and pharmacogenomics. It will also continue to in...
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potent...
— Exiting non-core businesses and geographies to prioritize higher-margin business initiatives — — Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — — Pro...
— COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors — — Co-Founder and former CEO Randy Scott returns as chairman — — Current chairman ...
Invitae (NVTA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend...
Worldwide Clinical Trials Enters Into a Strategic Collaboration With Invitae to Accelerate Clinical Trials for Rare D...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- #CRO--Worldwide Clinical Trials announces partnership with Invitae to improve global research with enhanced data insights for rare disease studies.
Invitae's problems make the stock a speculative lottery ticket.
Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?
Investors are taking a new, bearish analyst view on the company to heart.
Find out why the pros think these stocks could gain 200% or better.
SAN FRANCISCO , May 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conf...
New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access
- New data to be presented by Invitae at 2022 ASCO Annual Meeting show importance of genetic testing for all cancer patients - SAN FRANCISCO , May 26, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leadin...
Our roundtable found three biotechs with a nice cash cushion.
- New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization - SAN FRANCISCO , May 19, 2022 /PRNewswi...
Despite being down more than 60% year-to-date, Cathie Wood's Ark Invest remains confident in its thesis behind NVTA stock. The post Cathie Wood Just Bought More Invitae (NVTA) Stock.
The medical genetics company reported disappointing Q1 results.
Invitae (NVTA) delivered earnings and revenue surprises of -1.30% and 2.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than $100 million — — Broad OPEX controls and portfolio optim...
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer
Allelica and Invitae aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic information in...